The effect of genetic polymorphisms of cyclooxygenase 2 on acute pancreatitis in turkey

Pancreas

Volumn 39, Issue 3, 2010, Pages 371-376

  Özhan, Gül ^a   Yanar, Teoman Hakan ^a   Ertekin, Cemalettin ^a   Alpertunga, Buket ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acute pancreatitis; COX 2; Cyclooxygenases; SNP

Indexed keywords

CYCLOOXYGENASE 2;

ACUTE PANCREATITIS; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TURKEY (REPUBLIC);

ACUTE DISEASE; AGED; CYCLOOXYGENASE 2; FEMALE; GENETIC MARKERS; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TURKEY;

EID: 77950272438     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bae9ca     Document Type: Article

References (54)

1. Frossard JL, Morel P, Pastor CM. Why clinical trials might succeed in acute pancreatitis when they failed in septic shock. JOP. 2003; 4:11-16.
2. Forsmark CE, Toskes PP. Acute pancreatitisVmedical management. Crit Care Clin. 1995;11:295-309.
3. McKay CJ, Evans S, Sinclair MT, et al. High mortality rate from acute pancreatitis in Scotland, 1984-1995. Br J Surg. 1999;86: 1302-1305.
4. De Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis: an analysis of 279 cases. Gut. 1995;37:121-126.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
6. Johar D, Roth JC, Bay GH, et al. Inflammatory response, reactive oxygen species, programmed (necrotic-like and apoptotic) cell death and cancer. Rocz Akad Med Bialymst. 2004;49:31-39.
7. Haitian L, Weiming O, Chuanshu H. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4(4):1-13.
8. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. 2005;15:72-77.
9. Lowenfels AB, Maisonnneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433-1437.
10. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117: 50-59.
11. Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2004; 287:G315YG319.
12. Rao KN. Pathophysiology of pancreatitis: the role of prostaglandins. Prostaglandins. 1993;45:309-313.
13. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109(1):285-301.
14. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003;7:207-222.
15. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437.
16. Bhandari P, Bateman AC, Mehta RL, et al. Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of oesophagus. BMC Cancer. 2006;6:134-142.
17. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000;355:646-648.
18. Yip-Schneider MT, Wu H, Ralstin M, et al. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007;6(6):1736-1744.
19. Alhan E, Kalyoncu NI, Ercin C, et al. Effects of the celecoxib on the acute necrotizing pancreatitis in rats. Inflammation. 2004;28(5): 303-309.
20. Zabel-Langhennig A, Holler B, Engeland K, et al. Cyclooxygenase-2 transcription is stimulated and amylase secretion is inhibited in pancreatic acinar cells after induction of acute pancreatitis. Biochem Biophys Res Commun. 1999;265:545-549.
21. Makhija R, Cartmell M, Yang BM, et al. Cyclooxygenase-2 gene polymorphisms and acute pancreatitis. Pancreatology. 2002;2: 217-361.
22. Bradley EL. A clinically based classification system for acute pancreatitis. Arch Surg. 1993;128:586-590.
23. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 2004;221:889-897.
24. Daly AK, Steen VM, Fairbrother KS, et al. CYP2D6 multiallelism. Methods Enzymol. 1996;272:199-210.
25. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
26. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
27. Garcea G, Dennison AR, Steward WP, et al. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 2005;5:514-529.
28. Lindkvist B, Appelros S, Manjer J, et al. A prospective cohort study of smoking in acute pancreatitis. Pancreatology. 2008;8:63-70.
29. Kang RY, Freire MJ, Sigal E, et al. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol. 1996;35:711-718.
30. Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pyloriYrelated gastritis and gastric ulcer tissues in humans. Gut. 2000;46:782-789.
31. Sorli CH, Zhang HJ, Armstrong MB, et al. Basal expression of cyclooxygenase-2 and nuclear factorYinterleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci U S A. 1998;95:1788-1793.
32. Egan CG, Lockhart JC, Ferrell WR. Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation. J Physiol. 2004;557(2):635-643.
33. De Almeida JLJ, Jukemura J, Coelho AMM, et al. Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis. Clinics. 2006;61(4):301-306.
34. Song AM, Bhagat L, Singh VP, et al. Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1166YG1174.
35. Anderson GD, Hauser SD, Mcgarity KL, et al. Selective inhibition of cyclo-oxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. J Clin Invest. 1996;97:2672-2679.
36. Shaw G, Kamen R. A conserved AU sequence from the 3¶untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 1986;46(5):659-667.
37. Dixon DA. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des. 2004;10:635-646.
38. Cok SJ, Morrison AR. The 3¶-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem. 2001;276(25):23179-23185.
39. Chan IHS, Tang NLS, Leung TF, et al. Association of prostaglandin- endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children. Allergy. 2007;62:802-809.
40. Zhang Z, Sheng H, Shao J, et al. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia. 2000; 2(6):523-530.
41. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25(2):229-235.
42. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T9C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer. 2006;6:70-75.
43. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3¶UTR of cyclooxygenase-2/prostaglandin synthase-2 gene and risk of lung cancer in a Chinese population. Lung Cancer. 2005;48:11-17.
44. Campa D, Hung RJ, Mates D, et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:538-539.
45. Sorensen M, Autrup H, Tjonneland A, et al. A genetic polymorphism in prostaglandin synthase-2 (8473T9C) and the risk of lung cancer. Cancer Lett. 2005;226(1):49-54.
46. Ali IU, Luke BT, Dean M, et al. Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer. 2005;93(8):953-959.
47. Shen J, Gammon MD, Terry MB, et al. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8:71-80.
48. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. The cyclooxygenase-2 (PTGS2) 8473T9C polymorphisms associated with breast cancer risk. Clin Cancer Res. 2006;12(4):1392-1394.
49. Hakansson A, Bergman O, Chrapkowska C, et al. Cyclooxygenase-2 polymorphisms in Parkinson's disease. Am J Med Gen Part B. 2007;144B:367-369.
50. Gao J, Ke Q, Ma HX, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70(11): 908-915.
51. Sakoda LC, Gao YT, Chen BE, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 2006;27(6):1251-1256.
52. Cox DG, Buring J, Hankinson SE, et al. A polymorphism in the 3¶ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007; 9(1):3-7.
53. Cheng I, Liu X, Plummer SJ, et al. COX-2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557-561.
54. Shahedi K, Lindström S, Zheng SL, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668-672.